- Home
- NDLS vs RNTX Comparison
NDLS vs RNTX Comparison
Compare NDLS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- RNTX
- Stock Information
- Founded
- NDLS 1995
- RNTX 2001
- Country
- NDLS United States
- RNTX United States
- Employees
- NDLS N/A
- RNTX N/A
- Industry
- NDLS Restaurants
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- RNTX Health Care
- Exchange
- NDLS Nasdaq
- RNTX Nasdaq
- Market Cap
- NDLS 33.2M
- RNTX 28.0M
- IPO Year
- NDLS 2013
- RNTX N/A
- Fundamental
- Price
- NDLS $0.67
- RNTX $1.12
- Analyst Decision
- NDLS Buy
- RNTX Hold
- Analyst Count
- NDLS 2
- RNTX 1
- Target Price
- NDLS $3.00
- RNTX N/A
- AVG Volume (30 Days)
- NDLS 170.0K
- RNTX 128.0K
- Earning Date
- NDLS 11-05-2025
- RNTX 11-13-2025
- Dividend Yield
- NDLS N/A
- RNTX N/A
- EPS Growth
- NDLS N/A
- RNTX N/A
- EPS
- NDLS N/A
- RNTX N/A
- Revenue
- NDLS $494,752,000.00
- RNTX N/A
- Revenue This Year
- NDLS $1.19
- RNTX N/A
- Revenue Next Year
- NDLS N/A
- RNTX N/A
- P/E Ratio
- NDLS N/A
- RNTX N/A
- Revenue Growth
- NDLS N/A
- RNTX N/A
- 52 Week Low
- NDLS $0.55
- RNTX $1.04
- 52 Week High
- NDLS $1.74
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- NDLS 40.55
- RNTX 43.50
- Support Level
- NDLS $0.66
- RNTX $1.07
- Resistance Level
- NDLS $0.76
- RNTX $1.43
- Average True Range (ATR)
- NDLS 0.03
- RNTX 0.13
- MACD
- NDLS 0.00
- RNTX -0.01
- Stochastic Oscillator
- NDLS 18.18
- RNTX 13.03
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.